A Non-Invasive Double Chin Treatment Rises!

Double chin, medically known as submental fat, is an undesirable body feature that makes most sufferers hesitate to even look in the mirror. Though this condition is highly associated with obesity, many other factors do contribute including genetics, age or just the pulling of gravity. Regardless of the causes, sixty-eight percent of the people having double chin seek cosmetic intervention to rid themselves of it for good. Fortunately, a promising non-invasive solution has been introduced that will help many restore their self-confidence and stand bravely in front of any mirror.

Researchers based in Leverkusen, Germany, have recently conducted a successful trial of a new drug under the name ATX-101 which is designed to reduce excess fat deposits under the skin. When injected, the new drug causes the water to fill the cells until they fully expand and burst. As a result the localized fat dissolves and disappears along with the extra chin(s).

The treatment, which is aimed at those with moderate to severe fat beneath the chin, is known as Kybella. According to scientists, Kybella requires forty to seventy tiny injections to fully dissolve the fat and produce satisfying results within approximately sixteen weeks. The number of treatment sessions needed depends on the fat volume and other factors that are all determined during the consultation.

Besides dissolving fat, Kybella also destroys cell membranes. Hence, it should be delivered by an experienced, board-certified physician only. This measure is necessary to ensure that the drug is injected properly and that your procedure will not bring about serious side effects. The drug can also destroy other types of cells, so choosing the right doctor to perform the procedure is more than essential.

Currently, the use of Kybella is limited to the chin area as the researchers noted. If misused or administered improperly, side effects of such as swelling, pain, numbness and redness may rise in the injection site. Other more serious side effects may rise such as nerve damage in the jaw that cause an uneven smile or facial expression.

No anesthesia is requires for this procedure, making Kybella injection a more desirable option than its surgery-based counterparts. Nonetheless, it’s still up to the physician to decide whether traditional options such as liposuction or surgery would be more effective. After the treatment, lower rhytidectomy or neck lift may be desired by the patient to rid of the saggy skin that may appear when the fat is dissolved.

It is still too early to see the true potential of Kybella as an option for submental fat reduction. However, there is no denying that demands for safer and more effective injectable treatment for localized fat reduction are higher than ever. Ultimately, this study is a positive leap towards providing patients with a well-researched and clinically proven treatment to reduce localized double chin without going under the knife.